Journey Medical Corporation (Nasdaq: DERM) has received FDA approval for Emrosi™ (minocycline hydrochloride extended-release capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults. The company announced the approval on November 4, 2024, marking a significant milestone in their focus on dermatological treatments.
Clinical Data and Formulation
Emrosi™ is a modified-release formulation of minocycline designed to provide higher dermal concentrations compared to traditional doxycycline treatments. Data presented at the 44th Fall Clinical Dermatology Conference demonstrated that DFD-29 (40 mg), the formulation now approved as Emrosi™, achieves higher dermal concentrations than doxycycline from Day 1 onward at a similar dose. This is expected to translate into a clinically meaningful impact for patients with rosacea.
Commercial Launch
Journey Medical anticipates launching Emrosi™ in late Q1 or early Q2 of 2025. The company plans to host a conference call on February 5, 2025, to discuss the U.S. commercial launch plan for Emrosi™.
Journey Medical's Portfolio
Journey Medical Corporation is a commercial-stage pharmaceutical company focused on selling and marketing FDA-approved prescription pharmaceutical products for dermatological conditions. The addition of Emrosi™ will further strengthen their portfolio in addressing common skin conditions.
Financial Highlights
In addition to the FDA approval, Journey Medical reported total revenues of $14.6 million for the third quarter ended September 30, 2024. The company's focus on strategic acquisitions and product development continues to drive growth in the dermatology space.
